Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [658]
News [1456]
Articles [246]
Editorials [9]
Conferences [82]
elearning [17]
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause...
Prof Deborah Fenlon - Swansea University, Swansea, UK
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause in breast cancer survivors ( Prof Deborah Fenlon - Swansea University, Swansea, UK )
12 Dec 2019
What should be the HPV vaccine strategy for India?
Dr Rengaswamy Sankaranarayanan - WHO-IARC, Lyon, France
What should be the HPV vaccine strategy for India? ( Dr Rengaswamy Sankaranarayanan - WHO-IARC, Lyon, France )
7 Nov 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Dr Jonathan Ledermann - University College Hospital, London, UK )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian...
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer...
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
28 Sep 2019
More ovarian cancer patients benefit from maintenance combined targeted therapy
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
The potential of PARP inhibitors in new cancer groups and in combination with...
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...
The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation